Details
|
A UK based Biopharmaceutical Company named Xenova Group plc. develops novel drugs to treat cancer and cocaine, smoke addictions with a secondary focus in immunotherapy. The company has a broad pipeline of product candidates in clinical development which includes 3 cancer programmers as novel DNA targeting agents and xr303 which are in phase 1 for cancer indication; leading product candidate TransMid for the treatment of high-grade glioma, which is in phase 3 trial. Xenova is also developing 2 therapeutic vaccines for nicotine and cocaine addictions which are respectively in phase 1 and phase 2 trials. The company has about 80 workers. Xenova Group plc, was founded in 1987 and is located in Slough, United Kingdom.
|
